Seeking Alpha

Jazz Pharmaceuticals (JAZZ) +11.2% AH after agreeing to acquire privately-held EUSA Pharma for...

Jazz Pharmaceuticals (JAZZ) +11.2% AH after agreeing to acquire privately-held EUSA Pharma for as much as $700M in cash. EUSA's FDA-approved Erwinaze treatment blocks cell growth in patients with acute leukemia by cutting down asparagine levels in the bloodstream. Jazz expects the deal to add $210M-$230M in revenue and $0.75-$0.85/share in earnings.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs